Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Top signal score 19 of 100
Buys €304,353€1M Sells
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,477 of 26,280 companies
18.0
score / 100
Value
28
Quality
8
FCF yld-1.5%
Earn yld-2.5%
EV/EBITDA·
ROE-25%
Gross mgn7.5%
Net mgn-42%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
700,000 shares@ HK$3.9950.4% of flowShareXHKGHKEX:DA20171010E00272
Canonical exit: 1 Jan 2018 (T+90)
23 of 23 declarations
About Baijin Life Science Holdings Ltd.
On April 24, 2026, nine insiders of Baijin Life Science Holdings Ltd. filed purchases on the same day, which makes 2026 the busiest year in the record with 9 filings out of 23, all purchases and all within the last twelve months.
The known amounts date from 2017. Lai Yat Yuen, a director, bought EUR 304,353 on October 3, 2017, the only purchase with an amount among 10, then sold EUR 300,021 on October 11, 2017. Lee Tsz Hang sold EUR 1,173,885 on December 11, 2017. Those two are the only sales of the 7 in the record to carry an amount, worth EUR 1,473,906 in all. Purchases make up 59% of open-market trades.
Read moreShow less
The 23 filings, published from 2017 to 2026, come from 15 filers, the main ones all directors: SU Yaoyao (4 filings), CHEUNG Sze Ming (3) and Lai Yat Yuen (3). Insiders hold 26.2% of the capital, valued at HKD 1.5 billion, and filings appear a median of 5 days after the trade.